CTKB vs ESTA: fair value comparison
Cytek Biosciences, Inc. and Establishment Labs Holdings Inc. · Updated 2026-10-19
CTKB is still awaiting a full valuation verdict under our six-validated-windows standard. ESTA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, CTKB currently ranks higher by quality score.
| CTKB | ESTA | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $5.25 | $59.18 |
| 12-month range | $3.35–$6.09 | $47.80–$95.65 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #155 of 301 Healthcare | #156 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Low | High |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Downtrend |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: CTKB fair value analysis · ESTA fair value analysis